involved, studies of animal safety or, in the case of food-producing animals, human food safety studies (other than bioequivalence or residue studies) required for approval and conducted or sponsored by the applicant.

The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.

## List of Subjects

21 CFR Part 522

Animal drugs.

21 CFR Part 556

Animal drugs, Foods.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 522 and 556 are amended as follows:

# PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 522 continues to read as follows:

Authority: 21 U.S.C. 360b.

2. Section 522.812 is amended by revising paragraph (a), by redesignating paragraphs (d)(1), (d)(2), and (d)(3) as paragraphs (d)(1)(i), (d)(1)(ii), and (d)(1)(iii), respectively, by adding a new heading to paragraph (d)(1), and by adding paragraphs (c) and (d)(2) to read as follows:

#### §522.812 Enrofloxacin solution.

- (a) Specifications. Each milliliter of sterile solution contains either 22.7 milligrams of enrofloxacin when intended for use in dogs or 100 milligrams of enrofloxacin when intended for use in cattle.
- (c) Related tolerance. See § 556.228 of this chapter.
- (d) Conditions of use—(1) Dogs—(i) Amount. \* \* \*
- \* \* \* \* \*
- (2) Cattle—(i) Amount. Single-dose therapy: 7.5 to 12.5 milligrams enrofloxacin per kilogram of body

weight (3.4 to 5.7 milliliters per 100 pounds). Multiple-day therapy: 2.5 to 5.0 milligrams per kilogram of body weight (1.1 to 2.3 milliliters per 100 pounds) administered once daily for 3 to 5 days.

(ii) *Indications for use*. For the treatment of bovine respiratory disease (BRD) associated with *Pasteurella haemolytica*, *P. multocida*, and *Haemophilus somnus*.

(iii) Limitations. For subcutaneous use in cattle only. Do not inject more than 20 milliliters at each site. Do not slaughter within 28 days of last treatment. Do not use in cattle intended for dairy production. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. The effect of enrofloxacin on bovine reproductive performance. pregnancy, and lactation have not been determined. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

# PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD

3. The authority citation for 21 CFR part 556 continues to read as follows:

Authority: 21 U.S.C. 342, 360b, 371.

4. Section 556.228 is amended by redesignating the text as paragraph (a), by adding a heading to the newly redesignated paragraph (a), and by adding an introductory text and paragraph (b) to read as follows:

#### § 556.228 Enrofloxacin.

The acceptable daily intake for enrofloxacin is 3 micrograms per kilogram of body weight per day.
(a) *Chickens and turkeys.* \* \* \*

(b) Cattle. A tolerance of 0.1 part per million for desethylene ciprofloxacin (marker residue) has been established in liver (target tissue) of cattle.

Dated: August 25, 1998.

# Stephen F. Sundlof,

Director, Center for Veterinary Medicine. [FR Doc. 98–24497 Filed 9–11–98; 8:45 am] BILLING CODE 4160–01–F

#### **DEPARTMENT OF DEFENSE**

# Office of the Secretary

## 32 CFR Part 234

#### Conduct on the Pentagon Reservation

**AGENCY:** Department of Defense.

**ACTION:** Final rule.

**SUMMARY:** This document makes administrative amendments to the Department of Defense rule on "Conduct on the Pentagon Reservation".

**EFFECTIVE DATE:** October 14, 1998.

#### FOR FURTHER INFORMATION CONTACT:

L. Bynum or P. Toppings, 703/697–4111.

#### List of Subjects in 32 CFR Part 234

Alcohol abuse, Drug abuse, Drug testing, Federal buildings and facilities, Security measures, Traffic regulation.

Accordingly, 32 CFR Part 234 is amended as follows:

### PART 234—[AMENDED]

1. The authority citation for part 234 continues to read as follows:

Authority: 10 U.S.C. 131 and 2674(c).

#### § 234.1 [Amended]

2. Section 234.1, *Possession*, is amended by revising "of dominion" to read "or dominion" and *Weapons* by revising "and bow" to read "any bow".

# § 234.7 [Amended]

3. Section 234.7(e) is amended by removing the word "which" both times if appears.

## § 234.13 [Amended]

4. Sections 234.13(e) and 234.14 are amended by revising " $\S$  234.4(d)" to read " $\S$  234.3(d)".

### § 234.17 [Amended]

5. Section 234.17 is amended in paragraph (b)(3)(i) after the word trunk, by removing the word "to"; paragraph (b)(3)(ii) by revising the semicolon to a period, paragraph (c)(1)(ii) first sentence by revising "0.08 grams of" to read "0.08 grams or"; paragraphs (c)(2) and (c)(3)(i) by revising "(b)(1)" to read "(c)(1)"; paragraph (c)(4) by revising "(b)(1)(ii)" read "(c)(1)(ii)"; paragraph (c)(4)(ii) by revising "paragraph (c)(3) and (c)(4)(i)" to read "paragraphs (c)(3) and (c)(4)(i)" and paragraph (c)(3)(ii) first sentence by adding the word "to" after "submit."

Dated: September 8, 1998.

#### L.M. Bynum,

Alternate OSD Federal Register Liaison, Department of Defense.

[FR Doc. 98–24547 Filed 9–11–98; 8:45 am] BILLING CODE 5000–04–M